These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38112526)

  • 1. Pharmacokinetics and cardiac safety of clofazimine in children with rifampicin-resistant tuberculosis.
    Ali AM; P Solans B; Hesseling AC; Winckler J; Schaaf HS; Draper HR; van der Laan L; Hughes J; Fourie B; Nielsen J; Wiesner L; Garcia-Prats AJ; Savic RM
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0079423. PubMed ID: 38112526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children.
    Radtke KK; Hesseling AC; Winckler JL; Draper HR; Solans BP; Thee S; Wiesner L; van der Laan LE; Fourie B; Nielsen J; Schaaf HS; Savic RM; Garcia-Prats AJ
    Clin Infect Dis; 2022 Apr; 74(8):1372-1381. PubMed ID: 34286843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies.
    Ali AM; Radtke KK; Hesseling AC; Winckler J; Schaaf HS; Draper HR; Solans BP; van der Laan L; Hughes J; Fourie B; Nielsen J; Garcia-Prats AJ; Savic RM
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0144822. PubMed ID: 37358463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study.
    Li R; Ma JB; Yang H; Yang H; Yang XJ; Wu YQ; Ren F
    Microbiol Spectr; 2023 Aug; 11(4):e0104823. PubMed ID: 37310268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis.
    Abdelwahab MT; Court R; Everitt D; Diacon AH; Dawson R; Svensson EM; Maartens G; Denti P
    Antimicrob Agents Chemother; 2021 Jun; 65(7):e0268720. PubMed ID: 33875426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clofazimine and QT prolongation in the treatment of rifampicin-resistant tuberculosis: Findings of aDSM in Taiwan.
    Lin CJ; Chen JH; Chien ST; Huang YW; Lin CB; Lee JJ; Lee CH; Yu MC; Chiang CY
    J Microbiol Immunol Infect; 2024 Oct; 57(5):791-800. PubMed ID: 39160114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. QT prolongation in the STREAM Stage 1 Trial.
    Hughes G; Bern H; Chiang CY; Goodall RL; Nunn AJ; Rusen ID; Meredith SK
    Int J Tuberc Lung Dis; 2022 Apr; 26(4):334-340. PubMed ID: 35351238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort Study.
    Brust JCM; Gandhi NR; Wasserman S; Maartens G; Omar SV; Ismail NA; Campbell A; Joseph L; Hahn A; Allana S; Hernandez-Romieu AC; Zhang C; Mlisana K; Viljoen CA; Zalta B; Ebrahim I; Franczek M; Master I; Ramangoaela L; Te Riele J; Meintjes G
    Clin Infect Dis; 2021 Dec; 73(11):2083-2092. PubMed ID: 33882121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
    Motta I; Cusinato M; Ludman AJ; Lachenal N; Dodd M; Soe M; Abdrasuliev T; Usmanova R; Butabekov I; Nikolaevna TZ; Liverko I; Parpieva N; Moodliar R; Solodovnikova V; Kazounis E; Nyang'wa B-T; Fielding KL; Berry C
    Antimicrob Agents Chemother; 2024 Jul; 68(7):e0053624. PubMed ID: 38842323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis.
    Hughes JA; Solans BP; Draper HR; Schaaf HS; Winckler JL; van der Laan L; Radtke KK; Fourie B; Wiesner L; Hesseling AC; Savic RM; Garcia-Prats AJ
    Clin Infect Dis; 2022 Nov; 75(10):1772-1780. PubMed ID: 35377434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
    Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
    Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis.
    Denti P; Garcia-Prats AJ; Draper HR; Wiesner L; Winckler J; Thee S; Dooley KE; Savic RM; McIlleron HM; Schaaf HS; Hesseling AC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
    Turkova A; Waalewijn H; Chan MK; Bollen PDJ; Bwakura-Dangarembizi MF; Kekitiinwa AR; Cotton MF; Lugemwa A; Variava E; Ahimbisibwe GM; Srirompotong U; Mumbiro V; Amuge P; Zuidewind P; Ali S; Kityo CM; Archary M; Ferrand RA; Violari A; Gibb DM; Burger DM; Ford D; Colbers A;
    Lancet HIV; 2022 Sep; 9(9):e627-e637. PubMed ID: 35868341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.
    Thee S; Garcia-Prats AJ; Draper HR; McIlleron HM; Wiesner L; Castel S; Schaaf HS; Hesseling AC
    Clin Infect Dis; 2015 Feb; 60(4):549-56. PubMed ID: 25362206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Dooley KE; Rosenkranz SL; Conradie F; Moran L; Hafner R; von Groote-Bidlingmaier F; Lama JR; Shenje J; De Los Rios J; Comins K; Morganroth J; Diacon AH; Cramer YS; Donahue K; Maartens G;
    Lancet Infect Dis; 2021 Jul; 21(7):975-983. PubMed ID: 33587897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment.
    van Beek SW; Tanneau L; Meintjes G; Wasserman S; Gandhi NR; Campbell A; Viljoen CA; Wiesner L; Aarnoutse RE; Maartens G; Brust JCM; Svensson EM
    Open Forum Infect Dis; 2022 Aug; 9(8):ofac372. PubMed ID: 36043179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ECG monitoring in STREAM Stage 1: can we identify those at increased risk of QT prolongation?
    Hughes G; Bern H; Chiang CY; Goodall RL; Nunn AJ; Rusen ID; Meredith SK
    Int J Tuberc Lung Dis; 2022 Nov; 26(11):1065-1070. PubMed ID: 36281045
    [No Abstract]   [Full Text] [Related]  

  • 18. Dose-related adverse events in South African patients prescribed clofazimine for drug-resistant tuberculosis.
    Misra N; Padayatchi N; Naidoo P
    S Afr Med J; 2019 Dec; 110(1):32-37. PubMed ID: 31865940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis.
    Kengo A; Nabeemeeah F; Denti P; Sabet R; Okyere-Manu G; Abraham P; Weisner L; Mosala MH; Tshabalala S; Scholefield J; Resendiz-Galvan JE; Martinson NA; Variava E
    Antimicrob Agents Chemother; 2024 May; 68(5):e0158323. PubMed ID: 38597667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-related treatment outcomes in South African patients prescribed clofazimine for drug-resistant tuberculosis.
    Misra N; Padayatchi N; Naidoo P
    S Afr Med J; 2020 Dec; 111(1):61-67. PubMed ID: 33404008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.